Država: Kanada
Jezik: angleščina
Source: Health Canada
REMDESIVIR
GILEAD SCIENCES CANADA INC
J05AB16
REMDESIVIR
100MG
POWDER FOR SOLUTION
REMDESIVIR 100MG
INTRAVENOUS
15G/50G
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0162395002; AHFS:
APPROVED
2020-07-27
_Product Monograph _ _VEKLURY_ _ ®_ _ (remdesivir) powder for solution for infusion _ _Page 1 of 41_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR VEKLURY ® Remdesivir for injection, Powder for solution for infusion, 100 mg/vial (5 mg/mL when reconstituted) Nucleotide Prodrug Gilead Sciences Canada, Inc. 6711 Mississauga Rd, Suite 600 Mississauga, ON L5N 2W3 www.gilead.ca Date of Initial Authorization: July 27, 2020 Date of Revision: November 17, 2023 Submission Control No: 270659 _VEKLURY (remdesivir), indicated for: _ _- the treatment of coronavirus disease 2019 (COVID-19) in; _ • hospitalized adults and pediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen; • non-hospitalized adults and pediatric patients (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization and death. _has been issued marketing authorization with conditions, pending the results of trials to _ _verify its clinical benefit. Patients should be advised of the nature of the authorization. For _ _further information for VEKLURY please refer to Health Canada’s Notice of Compliance _ _with conditions - drug products web site:_ _https://www.canada.ca/en/health-_ _canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html_ _ _ _ _ _ _ _Product Monograph _ _VEKLURY_ _ ®_ _ (remdesivir) powder for solution for infusion _ _Page 2 of 41_ WHAT IS A NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C)? An NOC/c is a form of market approval granted to a product on the basis of PROMISING evidence of clinical effectiveness following review of the submission by Health Canada. Products authorized under Health Canada’s NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, a Preberite celoten dokument